Cargando...
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone. BTK inhibition has changed the treatment landscape of the...
Gardado en:
| Publicado en: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7874350/ https://ncbi.nlm.nih.gov/pubmed/33613931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989586 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|